VentriPoint Diagnostics Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
For the nine months, sales was CAD 0.007781 million compared to CAD 0.04006 million a year ago. Net loss was CAD 3.63 million compared to CAD 3.77 million a year ago. Basic loss per share from continuing operations was CAD 0.02 compared to CAD 0.02 a year ago.